Home » Newsletters » BioWorld Science

BioWorld Science

April 28, 2011

View Archived Issues

Novel oncolytic agent RX-5902 presented

MCT 4 expression is a marker of radiotherapy outcome in oropharyngeal squamous cell carcinoma

LB-100 enhances antitumor activity of combined veliparib/temozolomide treatment in vivo

Upsher-Smith Laboratories details development of extended-release topiramate formulation

Astellas Pharma claims new lysophospholipid LPA1 receptor antagonists

Aflibercept improves overall survival in phase III trial in metastatic colorectal cancer

TRAIL receptor agonist APG-350 potently induces apoptosis in cancer cells

Adeona Pharma completes trial of reaZin in patients with cognitive impairment

Centocor and Medivir patent new series of HCV NS5B inhibitors

Merck & Co. claims new mitogen-activated protein kinase inhibitors for cancer

Merck & Co. patents new positive allosteric modulators of muscarinic acetylcholine M1 receptor

A.P. Pharma meets with FDA to discuss NDA resubmission for APF-530

Rivastach patch is approved in Japan for Alzheimer's-type dementia

XenoPort and FDA agree on SPA for arbaclofen placarbil phase III trial

New ionotropic glutamate receptor agonists presented

FDA grants orphan drug status to active ingredient of Provectus Pharma's PV-10 in HCC

Genta begins tesetaxel trial in Japan in advanced cancer

Glubes approved in Japan to improve postprandial plasma glucose in patients with type 2 diabetes

IQ Therapeutics completes dosing in phase I IQNLF trial

European Commission approves Novartis' Rasilamlo for high blood pressure

Lipacreon approved in Japan as a pancreatic digestive enzyme replacement

FDA committee recommends approval of Victrelis for chronic HCV genotype 1 infection

FDA issues complete response letter regarding NDA for Aricept patch

Tarix Pharma enrolls first patient in phase I TXA-127 trial

Boehringer Ingelheim enrolls first patient in phase III BI-2013 trial in chronic hepatitis C

Baxter receives approval in Japan for inhaled anesthetic Suprane

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026
SERCA inhibitor shows promise for MSA-C treatment
BioWorld Science
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, researchers...